New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are ...

Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness ...

If you’ve noticed you’re getting winded faster, wheezing or coughing more, doctors say, don’t ignore it. Chronic obstructive ...

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

After a 3-hour flight, however, he developed dyspnea and leg edema, and CT pulmonary angiography confirmed acute PE. He was started on rivaroxaban (Xarelto); but while taking it, he experienced ...

ATX-04 is a selective ß2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWS ...

Cough sounds carry disease-specific acoustic signatures. By analysing these signatures using an AI-based algorithm, the ...

A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension (PAH) has missed its primary endpoint, triggering a 77% crash in the biotech’s share price. The company has paused ...

A European study finds hospitalisations and insufficient growth reduce health-related quality of life in childhood ...

Gossamer Bio's experimental treatment failed to significantly improve exercise capacity in patients with a rare lung ...